2007;18:733 9. S4.5.3-5. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1:767 76. S4.5.3-6. Roeters van Lennep JE, Heida KY, Bots ML, et al. Cardiovascular dis- ease risk in women with premature ovarian insufficiency: A system- atic review and meta-analysis. Eur J Prev Cardiol. 2016;23:178 86. S4.5.3-7. Edison RJ, Muenke M. Central nervous system and limb anoma- lies in case reports of first-trimester statin exposure. N Engl J Med. 2004;350:1579 82. S4.5.3-8. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007;64:496 509. S4.5.3-9. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG- CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26:175 7. S4.5.3-10. Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG. 2013;120:463 71. S4.5.3-11. Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2014;36:506 9. S4.5.3-12. McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss. Pharmacoepidemiol Drug Saf. 2017;26:843 52. S4.5.3-13. Fulcher J, O Connell R, Voysey M, et al. Efficacy and safety of LDL- lowering therapy among men and women: meta-analysis of individ- ual data from 174000 participants in 27 randomised trials. Lancet. 2015;385:1397 405. S4.5.3 14. Ley SH, Li Y, Tobias DK, et al. Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of car- diovascular disease in women. J Am Heart Assoc 2017;6;e006713. S4.5.3-15. 